A single course of low activity of Ac225-PSMA-617 combined with full activity 177Lu-PSMA-617 has been shown to have tolerable levels of xerostomia in 20 patients who had an insufficient response to 177Lu-PSMA-617 [116]. This evidence concerns the gene FOLH1 and xerostomia.